黑料网

XPENG (NYSE: XPEV) and Volkswagen Group China have signed a Memorandum of Understanding (MOU) to jointly develop one of China's largest super-fast charging networks. The strategic collaboration will provide mutual access to over 20,000 charging piles across 420 cities in China for customers of both companies.

The partnership leverages both companies' technological advantages in high-power liquid-cooled super-fast charging and their complementary coverage across China. The companies will also explore building co-branded super-fast charging stations to accelerate network expansion and improve operational efficiency.

This initiative marks the fourth milestone in the long-term strategic partnership between XPENG and Volkswagen Group, with both parties planning to explore additional strategic collaboration opportunities and technology partnerships.

Faraday Future (NASDAQ: FFIE) has announced an exclusive private showcase of its Faraday X (FX) prototype mules in Las Vegas, NV, scheduled for January 5-7, 2025. The event will be held at MEET Las Vegas and will feature interactive demonstrations of the vehicles' design, advanced features, and technological capabilities.

The company will host in-depth strategy discussions and roundtables focusing on the FX product line and technology developments. Following the private showcase, a new product category launch video will be broadcast on January 8, 2025, at 17:00 PST across FF's digital platforms, including FF.com, FF App, and various social media channels.

The FX brand emphasizes its commitment to delivering 'twice the performance at half the price' AIEV products to U.S. consumers, focusing on making performance- and technology-capable EVs more affordable.

Research Frontiers (REFR) and Gauzy (GAUZ) are showcasing SPD-SmartGlass technology at the 2024 CES show in Las Vegas. The companies will hold a press briefing and customer events at Gauzy's Booth 6516 in Automotive West Hall.

The presentation will focus on how smart glass technology is disrupting industries including aeronautics, automotive, and architecture. Notable implementations include Ferrari's integration of SPD Smart Glass in their top-selling SUV model. The global smart glass market, valued at $6.6 billion in 2023, is projected to grow at a 9.9% CAGR through 2030.

Visitors can experience firsthand demonstrations of smart glass applications in buildings, homes, automotive, aircraft, and trains, showcasing the technology's ability to transition from transparent to opaque in milliseconds.

Alibaba International announces its AI-powered B2B search engine, Accio, has reached 500,000 SME users since its November 2024 launch. The platform catalogs millions of suppliers across 7,600 product categories and is trained on over 200 million trade industry parameters.

The search engine's Accio Inspiration feature has driven a 30% increase in supplier conversion rates. During November-December 2024, over 50,000 SMEs utilized Accio for Black Friday and Christmas inventory sourcing. The platform maintains a net promoter score above 50 and was named 'Product of the Day' on Product Hunt on December 13, 2024.

Supporting five languages (English, French, German, Portuguese, Spanish), Accio features natural language processing capabilities, a dynamic product information interface, and an agent system for handling inquiries, payments, and after-sales support through Alibaba's infrastructure.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that the European Commission has extended the approval of Evkeeza庐 (evinacumab) to treat children aged 6-months and older with homozygous familial hypercholesterolemia (HoFH). Evkeeza is the first medicine in the EU approved for children as young as 6-months old with this ultrarare inherited condition that causes dangerously high cholesterol levels.

The approval is based on model-based extrapolation analysis predicting similar or higher LDL-C reduction in young patients compared to adults when receiving a 15 mg/kg dose every 4 weeks. Supportive data from five patients aged 1-4 years showed clinically meaningful LDL-C reduction consistent with older patients. The safety profile is expected to be similar to that in older pediatric patients.

Evkeeza is currently reimbursed and commercially available in eight countries including the UK, U.S., Canada, and Japan, with early access schemes in 13 additional countries.

HOOKIPA Pharma has issued an amendment to its Rule 2.4 announcement from January 2, 2025, regarding a potential combination with Poolbeg Pharma plc. The amendment corrects the ISIN of HOOKIPA's common stock from US43906K1007 to US43906K2096, which became effective after the company's 1-for-10 reverse stock split on July 9, 2024.

The company confirms having 9,655,022 shares of common stock, 2,399,517 shares of Class A common stock, 370 shares of Series A convertible preferred stock, 10,800 shares of Series A-1 convertible preferred stock, and 15,268 shares of Series A-2 convertible preferred stock outstanding. Class A common stock holders can convert ten shares into one common stock share, while Series A, A-1, and A-2 preferred stock can be converted into 100 common shares each, subject to ownership limitations.

argenx (Euronext & Nasdaq: ARGX), a global immunology company focused on severe autoimmune diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Tim Van Hauwermeiren, the company's CEO, will deliver a presentation on Monday, January 13, 2025 at 9:45 a.m. PT.

The presentation will be accessible through a live webcast on the Investors section of the argenx website (argenx.com/investors). A replay option will remain available on the company's website for approximately 30 days after the presentation.

Guardian Metal Resources (LON:GMET)(OTCQB:GMTLF) has successfully raised 拢750,000 through a placing with Premier Miton, a UK asset management company. The placing involves issuing 2,500,000 new ordinary shares at 拢0.30 per share, representing 2.00% of the enlarged issued share capital.

The funds will be used for working capital and to accelerate exploration and development activities at Pilot Mountain and, pending definitive agreement, at Tempiute. The placement demonstrates growing investor recognition of the importance of establishing domestic tungsten production in the U.S., given its critical applications in military and industrial sectors.

The placing shares are expected to be admitted to trading on AIM around January 9, 2025. Following admission, the company's total issued share capital will comprise 125,006,991 ordinary shares. As part of the commission, 120,000 broker warrants will be issued, exercisable at 拢0.375 per share with a 24-month expiry.

PureTech Health (Nasdaq: PRTC, LSE: PRTC) has announced the appointment of UBS as its UK Corporate Broker. The company, which is dual-listed on Nasdaq and London Stock Exchange, made this strategic move to enhance its corporate brokerage services in the United Kingdom.